Dianthus Therapeutics DNTH Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dianthus Therapeutics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dianthus Therapeutics's additional paid-in capital?
- Dianthus Therapeutics (DNTH) reported additional paid-in capital of $1.58B in Q1 2026.
- How has Dianthus Therapeutics's additional paid-in capital changed year-over-year?
- Dianthus Therapeutics's additional paid-in capital increased by 196.8% year-over-year, from $532.21M to $1.58B.
- What is the long-term trend for Dianthus Therapeutics's additional paid-in capital?
- Over 5 years (2020 to 2025), Dianthus Therapeutics's additional paid-in capital has grown at a 15.8% compound annual growth rate (CAGR), from $398.31M to $829.6M.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.